Urol. praxi. 2022;23(3):117-119 | DOI: 10.36290/uro.2022.033

Overactive bladder. Combination therapy with anticholinergic and beta-3 mimetic drugs

MUDr. Lukáš Horčička
GONA spol. s r. o., Urogynekologická ambulance, Praha

Overactive bladder is one of the most common causes of chronic complaints and impaired quality of life in developed countries. The differential diagnosis section points out serious oncological, neurological, and metabolic diseases exhibiting the symptoms of overactive bladder. The treatment of OAB including a combination of medicinal products is discussed in detail.

Keywords: overactive bladder, urgent incontinence, anticholinergics, beta-3 mimetics, combination therapy.

Accepted: October 10, 2022; Published: October 12, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horčička L. Overactive bladder. Combination therapy with anticholinergic and beta-3 mimetic drugs. Urol. praxi. 2022;23(3):117-119. doi: 10.36290/uro.2022.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurology and Urodynamic. 2002;21(2): 167-178. Go to original source... Go to PubMed...
    2. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they manage? A population-based prevalence study. B.J.Urol.Int. 2001;87:760-766. Go to original source... Go to PubMed...
    3. Chapple CR, et al. Solifenacin - a new therapeutic option of OAB? Kongres České urologické společnosti, Praha; říjen 2005.
    4. Martan A, et al. Inkontinence moči a ultrazvukové vyšetření dolního močového ústrojí u žen. PanMed, Praha; 2001.
    5. Zmrhal J, et al. Místo a význam urodynamických metod v současnosti. Moderní gynekologie a porodnictví. 2003;12(1):56-70.
    6. Zmrhal J. Základy diagnostiky v urogynekologii. Urol. listy. 2004;2(1):5-13.
    7. Tomolová Z, Zmrhal J, Voženílek J. Nálezy závažných patologií urotelu u pacientek s OAB ve vlastním materiálu. Praktická urogynekologie XIV.; celostátní konference Urogynekologické společnosti ČR, Mělník; prosinec 2005.
    8. Chmel R. Epidemiologické aspekty ženské močové inkontinence. Čas. Lék. Čes. 2005;2:95-97.
    9. Harding CK, et al. EAU Guidelines in Management of Non-Neurogenic Female LUTS, EAU, 2022.
    10. Sand PK. Latest Perspectives in Overactive Bladder Treat­ment; AUGS Symposium, 2018.
    11. Abrams P, et al. Combination Treatment with Mirabegron and Solifenacin in Patient with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study(Symphony). Eur Urol. 2015;67(3):577-588. Go to original source... Go to PubMed...
    12. https://dx.doi.org/10.1016/j.eururo.2016.02.030. Go to original source...
    13. https://doi.org/10.1016/j.eururo.2018.05.005. Go to original source...
    14. Herschorn S, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder. BJU Int. 2017;120(4):562-575. Go to original source... Go to PubMed...
    15. www.medscape.com/viewarticle/896394.
    16. https//doi.org/10.1016/j.eururo.2018.03.020.
    17. Nardulli R, et al. Combined antimuscarinics for treatment of neurogenic overactive bladder. Int J Immunopathol Pharmacol. 2012:35S-41S. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.